Altria Group, Inc. research snapshot
MO AI stock analysis reads Altria Group, Inc. as a mature U.S. nicotine company with strong pricing power, high cash generation, a market-leading cigarette franchise, and a 6.21% dividend yield, but the July 30, 2026 Q2 earnings miss and narrowed guidance broke the short-term uptrend. At the August 2, 2026 data cutoff, the latest verified close used here was $68.33 on July 31, 2026, with an implied market capitalization of about $114.09 billion. The analysis uses scenario ranges, not a certain price prediction. This is informational research and not investment advice.
Current price
$68.33
Market cap
$114.09 billion
AI score
58 / 100
Rating
High cash yield, earnings miss overhang
Trend status
Pullback above the 200-day, below the 50-day moving average
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Altria sells cigarettes, oral tobacco, nicotine pouches, cigars, and e-vapor products to adult U.S. consumers, with Marlboro still anchoring cash flow. | Medium-high |
| Moat | Moat comes from Marlboro brand power, retail distribution, regulation that raises barriers, pricing power, and scale in U.S. tobacco. | Medium-high |
| Management | Sal Mancuso became CEO in 2026 and Heather Newman joined as CFO, so management should be judged by smoke-free execution, capital allocation, leverage discipline, and dividend coverage. | Medium |
| Financial trend | 2025 revenue declined to $20.14 billion while net income was $6.947 billion; Q2 2026 adjusted EPS rose 2.8% to $1.48 but missed consensus, and the full-year guidance range was narrowed. | High |
| Valuation | The stock trades as a cash-return and dividend compounder, with trailing PE near 14.4x, forward PE near 11.9x, and FCF yield near 8% at the cutoff price. | Medium-high |
| Technical trend | MO closed below the 50-day moving average and above the 200-day moving average after the earnings drop, with RSI near 38.8, so the trend is short-term bearish within a longer uptrend. | Medium |
| Risk level | The thesis can fail if cigarette volumes fall faster than pricing, FDA rules restrict key products, NJOY or on! disappoint, or litigation and tax pressure rise. | High |
| AI confidence | High for historical financials, market-cap math, and risk mapping. Lower for forward share-price outcomes. | High data confidence |
| Investment certainty | Medium-low certainty because durable cash flow is balanced against structural volume decline and regulatory tail risk. | Medium-low |
MO AI stock forecast
The MO AI stock forecast uses three-year scenario ranges around the $68.33 cutoff close. The scenario framework produced a bullish value near $75 to $82, a base value near $64 to $73, and a bearish value near $54 to $62 using adjusted EPS growth and terminal PE assumptions. These are scenario outputs, not promises.
$75 to $82
More likely if adjusted EPS lands near the top of the $5.61 to $5.72 guidance range, Marlboro pricing offsets volume declines, on! and on! PLUS gain profitable share, and the stock recaptures the 50-day moving average with healthy volume.
$64 to $73
More likely if Altria keeps cash flow stable but investors apply a lower multiple because cigarette volumes keep declining and smoke-free growth remains gradual.
$54 to $62
More likely if earnings disappoint again, regulation or litigation damages pricing power, the smoke-free portfolio fails to scale, or the stock loses both the 200-day moving average and the $65 support zone.
MO AI technical analysis
MO AI technical analysis uses the July 31, 2026 close of $68.33 and public technical snapshots available at the August 2, 2026 data cutoff. The setup turned negative after the Q2 miss: price fell below the 50-day moving average of about $71.80 while staying above the 200-day moving average of about $65.57, and RSI dropped to about 38.8.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $68.33 | Latest verified close used for this page, dated July 31, 2026. |
| Near support | $66.83 to $67.56 | Recent daily lows around the July 30 and July 31 trading range, reported by StockAnalysis. |
| Deeper support | $65.57 | The approximate 200-day moving average reported by StockAnalysis. |
| Near resistance | $69.77 to $70.44 | Intraday highs after the earnings drop; a close above this zone would signal stabilization. |
| Upper resistance | $71.80 to $74.92 | The 50-day moving average at the lower end and the pre-earnings close of July 29 at the upper end. |
| 50-day moving average | About $71.80 | MO closed below this level after the July 30 earnings miss, which flipped the short-term trend. |
| 200-day moving average | About $65.57 | MO remains above this longer-term average, which keeps the broader uptrend intact for now. |
| Momentum | RSI near 38.8 | StockAnalysis reported RSI near 38.8, a weak reading that points to a short-term pullback rather than a confirmed reversal. |
| Volume | About 20.7 million on July 30 | Earnings-day volume was far above the average near 8.1 million, confirming the breakdown, while July 31 volume stayed elevated near 11.2 million. |
| Volatility | Low beta but event driven | Beta near 0.49 reduces market sensitivity, but earnings, FDA, and litigation headlines can create sharp gaps. |
| Invalidation | Close below $65.57, then $66.83 | A close below the 200-day moving average would challenge the longer trend; regaining the 50-day average near $71.80 would restore the short-term setup. |
MO AI trading strategy
The MO AI trading strategy is a rules-based research framework. It is not personalized advice. Traders should pair the setup with live price data, dividend dates, earnings releases, FDA headlines, position sizing, and predefined invalidation levels.
Wait for MO to reclaim the $69.77 to $70.44 resistance zone and then close back above the 50-day moving average near $71.80 with volume above the recent average.
A failed reclaim or a close below the $66.83 support area keeps the short-term setup bearish and invalidates a new long.
If MO pulls back toward the $65.57 to $66.83 zone without a negative filing, litigation, or FDA event, compare the yield, payout coverage, and volume trend before considering a reversion trade.
Do not average down if the pullback is caused by another earnings miss, regulatory change, or faster combustible volume decline.
Track Marlboro retail share, cigarette shipment decline, pricing, on! and on! PLUS share, NJOY re-entry, adjusted EPS guidance, debt, dividend coverage, and repurchase pace.
Reduce confidence when cash returns depend more on multiple expansion than on stable earnings and free cash flow.
Investment research summary
Altria monetizes adult nicotine demand through a dominant U.S. cigarette franchise, oral tobacco, nicotine pouches, cigars, and e-vapor products.
The moat is strongest in brand, distribution, scale, and regulatory barriers, but it narrows if consumers migrate faster than Altria can build profitable smoke-free platforms.
The failure path is faster cigarette volume decline, tougher FDA or tax policy, litigation shocks, poor smoke-free economics, and capital returns that mask eroding business quality.
The CEO transition to Sal Mancuso and the arrival of CFO Heather Newman make capital allocation, leverage discipline, dividend coverage, and smoke-free execution the key scorecard.
Nicotine demand is durable, but combustible tobacco is in structural decline. The long-term trend depends on whether Altria can shift profit pools without losing pricing power.
At $68.33, the stock offers a 6.21% dividend yield and near 8% FCF yield, but the Q2 miss shows the multiple can compress. The margin of safety is reasonable only if cash flow stays stable.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| MO closing price | $68.33 on July 31, 2026 | StockAnalysis real-time quote | August 2, 2026 |
| Market capitalization | $114.09 billion, verified as $68.33 x 1.67 billion shares | StockAnalysis statistics and market-cap math | August 2, 2026 |
| Q2 2026 adjusted EPS | $1.48, up 2.8%, versus $1.50 consensus | Altria Q2 2026 results and TheFly summary | August 2, 2026 |
| 2026 adjusted EPS guidance | Narrowed to $5.61 to $5.72 from $5.56 to $5.72, growth of 3.5% to 5.5% from the $5.42 base | Altria Q2 2026 results | August 2, 2026 |
| 2025 net revenues | $20.139 billion, down 1.49% | StockAnalysis financials from Fiscal.ai | August 2, 2026 |
| 2025 net income and EPS | $6.947 billion and $4.12 reported diluted EPS | StockAnalysis financials from Fiscal.ai | August 2, 2026 |
| Q2 2026 cigarette volumes | Reported domestic cigarette volumes fell 3.2% in Q2 and 2.8% in the first half | Altria Q2 2026 earnings call transcript | August 2, 2026 |
| Dividend | $4.24 annual dividend, 6.21% yield, 57 years of growth | StockAnalysis statistics | August 2, 2026 |
| Trailing and forward valuation | PE ratio near 14.4x trailing and 11.9x forward | StockAnalysis statistics | August 2, 2026 |
| Balance sheet and debt | $2.37 billion cash and $24.58 billion total debt, with debt/EBITDA near 1.9x | StockAnalysis statistics and Altria Q2 2026 call | August 2, 2026 |
| Free cash flow | Trailing twelve month free cash flow near $9.11 billion | StockAnalysis statistics | August 2, 2026 |
| Technical moving averages | 50-day about $71.80; 200-day about $65.57 | StockAnalysis statistics | August 2, 2026 |
| Analyst consensus | Consensus Hold with average price target near $70.64, range $59 to $82 | S&P Global analyst forecast via StockAnalysis | August 2, 2026 |
| Leadership | Sal Mancuso is Chief Executive Officer | StockAnalysis company profile | August 2, 2026 |
This MO AI stock analysis page is an informational tool only. It is not investment advice, a recommendation, or a promise of future returns. Forecast scenarios are based on available data as of August 2, 2026, may be incomplete, and can be wrong if new filings, market prices, FDA actions, litigation, dividend policy, or macro conditions change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
